Skip to Content
Merck

21-1430

Nicotinic acid

SAJ special grade, ≥99.5%

Synonym(s):

3-Picolinic acid, Niacin, Pellagra preventive factor, Pyridine-3-carboxylic acid, Vitamin B3

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C6H5NO2
CAS Number:
59-67-6
Molecular Weight:
123.11
EC Number:
200-441-0
UNSPSC Code:
12352005
PubChem Substance ID:
329752092
Beilstein/REAXYS Number:
109591
MDL number:
MFCD00006391

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

PVNIIMVLHYAWGP-UHFFFAOYSA-N

InChI

1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)

SMILES string

OC(=O)c1cccnc1

grade

SAJ special grade

assay

≥99.5%

form

powder

availability

available only in Japan

color

white

mp

236-239 °C (lit.)

solubility

ethanol: 12.5 g/L at 25 °C, water: soluble 180 g/L at 20 °C

density

1.473 g/cm3 at 25 °C

Looking for similar products? Visit Product Comparison Guide

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H319

Hazard Classifications

Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

379.4 °F - closed cup

flash_point_c

193 °C - closed cup

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
U2574
U7070
U1648
U5032
U2572

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
John R Guyton et al.
Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
Martina Lukasova et al.
Trends in pharmacological sciences, 32(12), 700-707 (2011-09-29)
Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in
E T Bodor et al.
British journal of pharmacology, 153 Suppl 1, S68-S75 (2007-11-27)
Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is somewhat
Antonio F Santidrian et al.
The Journal of clinical investigation, 123(3), 1068-1081 (2013-02-22)
Despite advances in clinical therapy, metastasis remains the leading cause of death in breast cancer patients. Mutations in mitochondrial DNA, including those affecting complex I and oxidative phosphorylation, are found in breast tumors and could facilitate metastasis. This study identifies
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service